After failed clinical trial, aging-focused drug company Unity Bio to cut staff by 30%
Unity Biotechnology Inc., whose clinical trial in osteoarthritis of the knee failed last month in clearing away dead cells thought to play a role in inflammation, will cut 30% of its workforce to focus its remaining cash on eye and brain diseases.
One of the first wave of so-called aging drug companies — concentrating on therapies to tackle aging-associated diseases — the South San Francisco company (NASDAQ: UBX) said Tuesday it plans to end the year with about 75 full-time employees.
The…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
More News: Biotechnology | Brain | Clinical Trials | Health Management | Neurology | Osteoarthritis | Pharmaceuticals